S0300, Celecoxib in Preventing Breast Cancer in Premenopausal Women
Stopped early · Phase 2 · Has a placebo group
Conditions studied: Breast Cancer
In brief
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of celecoxib may be effective in preventing breast cancer. PURPOSE: This randomized phase II trial is studying how well celecoxib works in preventing breast cancer in premenopausal women who are at risk for developing the disease.
Key facts
- Study ID
- NCT00088972
- Run by
- SWOG Cancer Research Network
- People needed
- 8
- Starts
- 2004-11-01
- Expected to finish
- 2009-07-01
- Last updated by the study team
- 2018-08-10
Who can join
Age: 18 and older, up to 120. Sex: female. Healthy volunteers: not accepted.
Where it is running
- Glendale Memorial Hospital Comprehensive Cancer Center — Glendale, California, United States
- University of New Mexico Cancer Center — Albuquerque, New Mexico, United States
- Baylor University Medical Center - Houston — Houston, Texas, United States
- Ben Taub General Hospital — Houston, Texas, United States
- Methodist Hospital — Houston, Texas, United States
- St. Luke's Texas Cancer Institute at St. Luke's Episcopal Hospital — Houston, Texas, United States
- Veterans Affairs Medical Center - Houston — Houston, Texas, United States
- Swedish Cancer Institute at Swedish Medical Center - First Hill Campus — Seattle, Washington, United States
- University Cancer Center at University of Washington Medical Center — Seattle, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.